A Multicenter Phase I/Ib open label dose escalation study of ABBV-399, and antibody drug conjugate, in subjects with advanced solid tumors.
Clinical Trial Grant
Awarded By
AbbVie Inc.
Start Date
March 1, 2014
End Date
September 2, 2024
Awarded By
AbbVie Inc.
Start Date
March 1, 2014
End Date
September 2, 2024